Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Trial Details

NCT ID

NCT05954897

Phase

PHASE2

Sponsor

Guangdong Provincial People's Hospital

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• 18 years or older.
• HCC was diagnosed according to the Criteria for Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) and American Association for the Stu…
• Classified as stage C according to the Barcelona Clinic Liver Cancer (BCLC) staging system.
• A dominant mass in theliver with or without extrahepatic oligometastasis, which was defined as up to three metastatic lesions in up to two organs w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.